AustraliaDaily Briefs

Daily Brief Australia: APA Group, 3P Learning, Recce Ltd and more

In today’s briefing:

  • APA Group Placement – Well Flagged Deal, but Lacks in Accretion
  • 3P Learning (3PL): Steady Through the 3Rs, Eyes on FY24
  • Recce Pharmaceuticals – R327 progressing in rapid infusion study


APA Group Placement – Well Flagged Deal, but Lacks in Accretion

By Clarence Chu

  • APA Group (APA AU) is looking to raise A$675m (US$430m) in its primary follow-on to partially fund its acquisition of the Alinta Energy assets in the Pilbara region.
  • The deal is a well flagged one with APA having been one of the last remaining bidders on the asset. Short interest has been on the rise as well.
  • However, the deal doesn’t seem accretive at our end, and the results reported today seemed to have missed analyst expectations.

3P Learning (3PL): Steady Through the 3Rs, Eyes on FY24

By Anik Siwach

  • Holistic Educational Suite: 3PL enriched its product portfolio, with the APAC debut of WritingLegends and BrightPath Assessement. 
  • Steady Financial Growth: Amidst challenges in the UK, 3PL’s 9% ARPU growth highlights its consistent performance and market strength. 
  • Setting the Pace: With attractive-priced offerings, an integrated product approach, and an innovative teacher training vision, 3PL is expected to continue growing its top line as more schools join. 

Recce Pharmaceuticals – R327 progressing in rapid infusion study

By Edison Investment Research

Recce recently reported the completion of its data review from its earlier long-infusion Phase I study of the intravenous (IV) RECCE 327 (R327) formulation, confirming that the drug candidate shows favourable safety characteristics, a robust dose-dependent pharmacokinetic drug concentration response, as well as evidence of increased drug concentration into the urinary tract. The company is proceeding with a Phase I/II study assessing using a more rapid infusion rate, with recent completion of the first 2,500mg cohort of the Phase I part ahead of schedule. Obtaining financing is a near-term strategic priority given the cash at hand (A$1.6m at 30 June 2023), and the company’s current cash runway is short (into late Q3 CY23). Recce has signalled that it is seeking to raise A$12–15m. After rolling forward our estimates and updating forex assumptions, we obtain an rNPV valuation of A$562.4m (or A$3.15 per share), up from A$535.6m previously.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars